

Global Vaccine Market Report 2022 focuses on consistent inequities

10 November 2022 | News

Vaccines prioritised by WHO are not being developed or fully invested in due to limited profit potential

The World Health Organisation- WHO's Global Vaccine Market Report 2022, published on 9 November, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently struggling to access vaccines that are in-demand by wealthier countries.

Limited vaccine supply and unequal distribution drive global disparities. The human papillomavirus (HPV) vaccine against cervical cancer has only been introduced in 41% of low-income countries, even though they represent much of the disease burden, compared to 83% of high-income countries.

Affordability is also an obstacle to vaccine access. While prices tend to be tiered by income, price disparities see middle-income countries paying as much, or even more, than wealthier ones for several vaccine products.

To drive ambitious action to deliver equitable access to vaccines, the report calls on governments to act on: clear immunisation plans and more aggressive investment and stronger oversight of vaccine development, production and distribution; regional research and manufacturing hubs; and pre-agreeing rules for government collaboration in times of scarcity on issues such as vaccine distribution, intellectual property and the circulation of inputs and goods.

Recommended actions for industry include: focusing research efforts on WHO priority pathogens, ensuring transparency, facilitating technology transfer, and committing to specific equity-driven allocation measures. International organizations and partners should prioritize Immunization Agenda 2030 goals, support country-driven initiatives and push for the application of resolutions on market transparency.